This study is for patient that have been diagnosed with muscle-invasive bladder cancer. The investigational drug in this study is Nivolumab and other chemotherapy treatments is given by intravenous (IV) infusion and the BMS-986205 is given in pill form.The purpose of this study is to test the effectiveness (how well the drug works), safety, and side effects of the experimental drug called BMS-986205, when BMS-986205 is added to another cancer medicine called nivolumab plus chemotherapy for subjects who have bladder cancer that has grown into the muscle wall of the bladder.
This clinical research study is with patients who have kidney cancer (renal cell carcinoma or RCC) that has advanced or spread to other areas of the body. the study drugs are cabozantinib (XL184) in combination with nivolumab plus ipilimumab, or placebo in combination with nivolumab plus ipilimumab. this study will last about 15-21 months.
The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called NKTR-214, when combined with nivolumab versus nivolumab given alone, both before and after radical cystectomy versus standard of care in participants with muscle invasive bladder cancer (MIBC) who are cisplatin ineligible. The treatment will be given to participants, who have bladder cancer that has invaded into the bladder muscle, and who cannot receive a chemotherapy treatment called cisplatin. The standard treatment in this situation is to have surgery to remove the bladder (radical cystectomy). In this trial, one-third of patients will be assigned to have NKTR-214 and nivolumab before and after surgery, one-third will have nivolumab before and after surgery, and one-third will have surgery alone. NKTR-214 and nivolumab are treatments that boost the immune system to fight cancer. It is unknown if NKTR-214 and nivolumab or nivolumab alone will have an effect (good, bad, or no effect) on the participant or their cancer.
Adult males are being asked to volunteer because they have been diagnosed to have bladder cancer that has spread and subjects tumor has a specific type of biomarker called PD-L1 (biomarkers can help to tell us what is going on in subjects body).This is a research study to find out if experimental medications called pembrolizumab and lenvatinib, when administered together. Participants can expect to be on this study for 2 years.
This study is for patients with an advanced rare genitourinary cancer. The purpose is to test the good and bad effects of the drugs called cabozantinib, nivolumab and ipilimumab, when given in combination.
This study is for patients with invasive bladder cancer. The purpose of this study is to determine if a certain group of patients can avoid standard surgery called a radical cystectomy with pelvic lymph node dissection based on whether their tumor has a certain genetic marker and the stage of their cancer after finishing chemotherapy.
The purpose of this study is to assess how effective the combination of avelumab and NHS-IL12 is in subjects with solid tumors. It will also collect more information on how safe and well-tolerated the combined study drugs are. Subjects will undergo a series of treatment cycles, each lasting 28 days. On Day 1 of each cycle, you will receive NHS IL12 immediately followed by avelumab on scheduled days. You will be assigned to receive avelumab every two weeks or to receive avelumab once a week. Both you and your study doctor will know which dose of study drugs you are receiving during the study.
This is a study that will test how an experimental drug (enfortumab vedotin) combined with a kind of anticancer drug called an immune checkpoint inhibitor (CPI) affects patients with cancer of the urinary system (urothelial cancer). This type of cancer includes cancer of the bladder, renal pelvis, ureter or urethra that has spread to nearby tissues or to other areas of the body.
This study will be conducted at MUSC and the VA on adult patients with newly diagnosed metastatic prostate cancer. The purpose of this study is to see if giving several cycles of docetaxel before androgen deprivation therapy (degarelix) improves outcomes, including survival rates, among men with metastatic prostate cancer. Patients will undergo screening assessments to see if they are eligible. Once on study, subjects will receive 6 cycles of docetaxel (cycle = 21 days). During cycle 4, subjects will begin taking degarelix every 28 days for up to 7 months.